澳门大阳城集团2138网站|主頁-欢迎您!

ENGLISH

检测到您当前使用浏览器版本过于老旧,会导致无法正常浏览网站;请您使用电脑里的其他浏览器如:360、QQ、搜狗浏览器的极速模式浏览,或者使用谷歌、火狐等浏览器。

下载Firefox
邓贤明教授博导

邮  箱:xmdeng@xmu.edu.cn

职称/职务:教授 博士生导师

联系方式:+86-592-2184180

  • 个人简介
  • 科研领域
  • 代表性成果

2001年,澳门大阳城集团化学专业,学士学位;
2006年,中科院上海有机化学研究所有机化学专业,博士学位;
2006-2011年,哈佛医学院Dana-Farber癌症研究所,博士后;
2011年至今,澳门大阳城集团澳门大阳城集团2138网站,闽江学者特聘教授/微生物药物课题组学科带头人;
2020年,获国家杰出青年科学基金资助。
B.S. 2001, Xiamen University, Chemistry;
Ph.D. 2006, Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences, Organic Chemistry;
Research Fellow, Dana-Farber Cancer Institute, Harvard Medical School, 2006-2011;
Principal Investigator of Chemical Biology and Medicinal Chemistry Group, School of Life Sciences, Xiamen University, 2011 to Present.

化学生物学和药物化学。在化学生物学方面,我们集中于设计并合成新颖的针对蛋白激酶(Protein Kinase)和表观遗传蛋白(Epigenetic Enzyme)的小分子抑制剂,并运用这些功能小分子为工具,发现和解决信号传导通路、神经生物学和癌症中的新问题。在药物化学方面,以化学生物学研究成果为基础,结合传统的药物化学手段(构效关系研究、药代动力学和毒理学研究)进一步优化小分子工具化合物,以期发展针对癌症等相关疾病的“靶向治疗”药物。
Our research is focused on two major areas: chemical biology and medicinal chemistry. At the interface of chemistry and biology, we use organic synthesis to create new chemical tools for studying biological problems in human health and disease. These functional small-molecule tools are applied to control and elucidate cellular signal transduction in cancer, stem cell, and neural diseases. Second, we pursue established medicinal chemistry approaches including structure activity relationship (SAR) study and pharmacokinetics modification to optimize pre-clinical drug candidates. We're working to address the following general questions: a) How can we develop small-molecule modulators with selectivity towards desired targets such as protein kinases and epigenetic enzymes? b) How can we use discovered-small-molecule tools to dissect the molecular signaling pathways? c) How can we develop the 'lead' of targeted-drug from the tool compound?

代表性论文(# co-first author, * Corresponding author):

1. Ma, T.; Tian, X.; Zhang, B.; Li, M.; Wang, Y.; Yang, C.; Wu, J.; Wei, X.; Qu, Q.; Yu, Y.; Long, S.; Feng, J.-W.; Li, C.; Zhang, C.; Xie, C.; Wu, Y.; Xu, Z.; Chen, J.; Yu, Y.; Huang, X.; He, Y.; Yao, L.; Zhang, L.; Zhu, M.; Wang, W.; Wang, Z.-C.; Zhang, M.; Bao, Y.; Jia, W.; Lin, S.-Y.; Ye, Z.; Piao, H.-L.; Deng, X. *; Zhang, C.-S. *; Lin, S.-C. *, Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 2022, 603 (7899), 159-165. (Recommended by Faculty Opinions rated as exceptional) .
2. Yin, C.; Zhu, B.; Zhang, T.; Liu, T.; Chen, S.; Liu, Y.; Li, X.; Miao, X.; Li, S.; Mi, X.; Zhang, J.; Li, L.; Wei, G.; Xu, Z.; Gao, X.; Huang, C.; Wei, Z.; Goding, C. R.; Wang, P.*; Deng, X.*; Cui, R.* Pharmacological targeting of STK19 inhibits oncogenic NRAS driven melanomagenesis. Cell, 2019, 176, 1113-1127.e16. (Highlighted by Cancer Discovery) .
3. Fan, F.; He, Z.; Kong, L. L.; Chen, Q.; Yuan, Q.; Zhang, S.; Ye, J.; Liu, H.; Sun, X.; Geng, J.; Yuan, L.; Hong, L.; Xiao, C.; Zhang, W.; Li, Y.; Wang, P.; Huang, L.; Wu, X.; Ji, Z.; Wu, Q.; Xia, N. S.; Gray, N. S.; Chen, L.; Yun, C. H.*; Deng, X.*; Zhou, D.* Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci. Transl. Med. 2016, 8, 352ra108. (Cover story, Highlighted by Nature Reviews Gastroenterology & Hepatology)
4. Lu, Y.; Fan, Z.; Zhu, S. J.; Huang, X.; Zhuang, Z.; Li, Y.; Deng, Z.; Gao, L.; Hong, X.; Zhang, T.; Li, L.; Sun, X.; Huang, W.; Zhang, J.; Liu, Y.; Zhang, B.; Jiang, J.; Gui, F.; Wang, Z.; Li, Q.; Song, S.; Huang, X.; Wu, Q.; Chen, L.; Zhou, D.; Zhang, J.*; Yun, C. H.*; Chen, L.*; Deng, X.*, A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol. Med. 2022, 14 (1), e14296. (Highlighted by ALK Positive Org.) .
5. Zhang, J.*; Bhuiyan, M. I. H.; Zhang, T.; Karimy, J. K.; Wu, Z.; Fiesler, V. M.; Zhang, J.; Huang, H.; Hasan, M. N.; Skrzypiec, A. E.; Mucha, M.; Duran, D.; Huang, W.; Pawlak, R.; Foley, L. M.; Hitchens, T. K.; Minnigh, M. B.; Poloyac, S. M.; Alper, S. L.; Molyneaux, B. J.; Trevelyan, A. J.; Kahle, K. T.*; Sun, D.*; Deng, X.*, Modulation of brain cation-Cl− cotransport via the SPAK kinase inhibitor ZT-1a. Nat. Commun. , 2020, 11, 78. (Highlighted by The Medical News) .
6. Wang, Y.; Zhang, L.; Wei, Y.; Huang, W.; Li, L.; Wu, A. A.; Dastur, A.; Greninger, P.; Bray, W. M.; Zhang, C. S.; Li, M.; Lian, W.; Hu, Z.; Wang, X.; Liu, G.; Yao, L.; Guh, J. H.; Chen, L.; Wang, H. R.; Zhou, D.; Lin, S. C.; Xu, Q.; Shen, Y.; Zhang, J.; Jurica, M. S.; Benes, C. H.; Deng, X.*, Pharmacological Targeting of Vacuolar H(+)-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chem. Biol. 2020, 27 (11), 1359-1370.e8.
7. Li, Y.; Liu, Z.; Li, L.; Lian, W.; He, Y.; Khalil, E.; Mäkilä, E.; Zhang, W.; Torrieri, G.; Liu, X.; Su, J.; Xiu, Y.; Fontana, F.; Salonen, J.; Hirvonen, J.; Liu, W.; Zhang, H.*; Santos, H. A.*; Deng, X.*, Tandem-Mass-Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition. Adv. Science 2020, 7 (15), 2001129.
8. Zhang, L.; Wang, Y.; Huang, W.; Wei, Y.; Jiang, Z.; Kong, L.; Wu, A. A.; Hu, Z.; Huang, H.; Xu, Q.; Li, L.; Deng, X.*, Biosynthesis and Chemical Diversification of Verucopeptin Leads to Structural and Functional Versatility. Org. Letters 2020, 22 (11), 4366-4371.
9. Gui, F.; Jiang, J.; He, Z.; Li, L.; Li, Y.; Deng, Z.; Lu, Y.; Wu, X.; Chen, G.; Su, J.; Song, S.; Zhang, Y. M.; Yun, C. H.; Huang, X.; Weisberg, E.; Zhang, J.*; Deng, X.*, A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk(C481S) mutation in B-cell malignancies. Br. J. Pharmacol. 2019, 176, 4491-4509.
10. Tian, M.; Zeng, T.; Liu, M.; Han, S.; Lin, H.; Lin, Q.; Li, L.; Jiang, T.; Li, G.; Zhang, T.; Kang, Q.; Deng, X.*; Wang, H. R.*, A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases. J. Biol. Chem. 2019, 294 (8), 2880-2891.
11. Liu, Z.; Li, Y.; Li, W.; Lian, W.; Kemell, M.; Hietala, S.; Figueiredo, P.; Li, L.; Mäkilä, E.; Ma, M.; Salonen, J.; Hirvonen, J. T.; Liu, D.; Zhang, H.*; Deng, X.*; Santos, H. A.*, Close-loop dynamic nanohybrids on collagen-ark with in situ gelling transformation capability for biomimetic stage-specific diabetic wound healing. Materials Horizons 2019, 6, 385-393.
12. Huang, W.; Sun, X.; Li, Y.; He, Z.; Li, L.; Deng, Z.; Huang, X.; Han, S.; Zhang, T.; Zhong, J.; Wang, Z.; Xu, Q.; Zhang, J.; Deng, X.* Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities. J. Med. Chem. 2018, 61, 5424-5434.
13. Liu, Z.; Li, Y.; Li, W.; Xiao, C.; Liu, D.; Dong, C.; Zhang, M.; Mäkilä, E.; Kemell, M.; Salonen, J.; Hirvonen, J. T.; Zhang, H.*; Zhou, D.*; Deng, X.*; Santos, H. A.* Multifunctional Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles, and Acetalated Dextran for Liver Regeneration and Acute Liver Failure Theranostics. Adv. Materials 2018, 30, e1703393.
14. Ning, N., Yu, Y., Wu, M.; Zhang, R., Zhang, T., Zhu, C., Huang, L., Yun, C. H., Benes, C. H., Zhang, J., Deng, X.*, Chen, Q.*, Ren, R.*, A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors. Cancer Res. 2018, 78, 5949-5957.
15. Jiang, J.; Gui, F.; He, Z.; Li, L.; Li, Y.; Li, S.; Wu, X.; Deng, Z.; Sun, X.; Huang, X.; Huang, W.; Han, S.; Zhang, T.; Wang, Z.; Jiao, B.; Song, S.; Wang, H.-R.; Chen, L.; Zhou, D.; Liu, Q.; Ren, R.*; Zhang, J.*; Deng, X.* Targeting BRK-positive breast cancers with small molecule kinase inhibitors Cancer Res. 2017, 77, 175-186. (Highlighted by BioWorld™️) .
16. Jiang, H.; He, H.; Chen, Y.; Huang, W.; Cheng, J.; Ye, J.; Wang, A.; Tao, J.; Wang, C.; Liu, Q.; Jin, T.; Jiang, W.*; Deng, X.*; Zhou, R.* Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 2017, 214, 3219-3238. (Highlighted by Nature Reviews Rheumatology).
17. He, H.; Jiang, H.; Chen, Y.; Ye, J.; Wang, A.; Wang, C.; Liu, Q.; Liang, G.; Deng, X.*; Jiang, W.*; Zhou, R.* Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 2018, 9, 2550.
18. Wang, Y.; Qi, S.; Zhan, Y.; Zhang, N.; Wu, A.; Gui, F.; Guo, K.; Yang, Y.; Hu, Z.; Zheng, Z.; Song, S.; Xu, Q.; Shen, Y.*; Deng, X.* Aspertetranones A-D, Meroterpenoids from the Marine Algal-associated Fungus Aspergillus sp. J. Nat. Prod. 2015, 78, 2405-10.
19. Deng, X.#, Dzamko, N.# , Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J. D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 2011, 7, 203-5.
20. Yang, Q.#, Deng, X.#, Lu, B.#, Cameron, M.; Fearns, C., Patricelli, M. P.; Yates, J. R., 3rd; Gray, N. S.; Lee, J. D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18, 258-67.

荣誉、奖励及参加学术团体的情况:

福建省第十四届“青年科技奖”,2017年
“药明康德生命化学研究奖”学者奖,2018年
澳门大阳城集团“田昭武学科交叉奖”特等奖,2019年
福建省自然科学奖一等奖(第三完成人),2019年